Literature DB >> 28677780

Spectrum construction of differentially expressed circular RNAs in patients with leukoaraiosis and function analysis of differentially expressed genes.

Te Mi1, Changjiang Luo2, Yawei Hu3, Chuanqiang Qu4, Xiang Wang4, Shougang Guo4, Yifeng Du4.   

Abstract

Circular RNAs (circRNAs) are class of endogenous RNAs that have a role in the regulation of gene expression. The present study aimed to investigate the diagnostic value and role of circRNA in the pathogenesis of leukoaraiosis (LA). The present study performed Arraystar Human circRNA Array analysis of 6 samples from LA cases and 6 samples from control cases. Differentially expressed (DE) circRNAs between two samples were identified through fold‑change (>1.5‑fold) screening. Afterwards, based on DE circRNAs, the gene ontology (GO) analysis of upregulated DE genes identified from DE circRNAs demonstrated that DE genes were primarily associated with cellular metabolic processes, membrane‑bound organelles and binding. However, none were enriched in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. Downregulated DE genes were enriched in cellular localization, cytoplasm and kinase binding. For the KEGG pathways, the downregulated DE genes were primarily associated with the insulin signaling pathway. The results of the present study indicated that the DE genes from differently expressed circRNAs may have an important role in the pathogenesis of LA and may be a novel targfet for further research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28677780      PMCID: PMC5548020          DOI: 10.3892/mmr.2017.6871

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


Introduction

Leukoaraiosis (LA), a common form of cerebral white matter lesion (WML), is characterized by punctuate or patchy hyperintensities in the periventricular or subcortical white matter observed via magnetic resonance imaging (MRI). Although it remains asymptomatic, LA is not considered to be benign, and has been demonstrated to be associated with poor clinical outcomes and increased risk of disability, dementia, depression, stroke, and the overall morbidity and mortality (1). LA is associated with increased age, hypertension, diabetes mellitus, history of stroke and chronic atherosclerotic diseases (2). As hypertension is reported to be one of the major determinants of WMLs, the present study only included subjects with a history of hypertension. Despite intensive research, an understanding of the pathological mechanism remains incomplete, and is likely to be multifactorial. Therefore, identifying biomarkers is essential to improve the early diagnosis of LA. Circular RNAs (circRNAs) are a class of endogenous RNAs that have a stable structure (3), which is a clear advantage of using circRNAs as a diagnostic marker. Previous studies have demonstrated that circRNAs are involved in the development of several types of diseases, including nervous system disorders (4,5). However, limited information is available regarding the association of circRNAs with LA. The present study, based on the hypertension population, compared the circRNA expression profiles of LA sufferers and controls. By performing a circRNA array analysis and reverse transcription-quantitative polymerase chain reaction (RT-qPCR), the present study demonstrated that certain circRNAs, including has_circ_102533 and has_circ_103783, may have potential as a novel type of biomarker for the diagnosis of LA. In addition, the gene ontology and KEGG analysis of differentially expressed (DE) genes may contribute to an improved understanding of the pathogenesis of LA.

Materials and methods

Subjects and clinical specimens

The current study was performed in accordance with the guidelines of the Helsinki Declaration. Written informed consent was obtained from all subjects and the Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong University (Jinan, China) approved all aspects of the present study. A total of 30 subjects were recruited between August 2014 and September 2015 at Shandong Provincial Hospital Affiliated to Shandong University. All cases had a history of hypertension for 5–15 years. The groups were as follows: Test (LA sufferers; n=20; 7 males and 13 females) and control (no LA; n=10; 3 males and 7 females). The mean age was 58±5.7 years. The subjects had a mean systolic pressure of 150±7.1 mmHg and a mean diastolic pressure of 84±4.2 mmHg. LA is defined as punctuate or patchy hyperintensities in the periventricular or subcortical white matter, observed by MRI. Hypertension is defined as a history of high blood pressure (≥140/90 mmHg) reported by the respondent, or by the current use of antihypertensive medication. None of the cases suffered from diabetes mellitus, heart diseases, dyslipidemia, hypotension, immune system diseases, hematological disorders, malnutrition, malignant tumors, serious liver and kidney diseases (including severe hepatitis or nephritis), liver or kidney failure, or had a history of heavy smoking (20 cigarettes daily) or alcoholism. Fresh fasting peripheral blood samples (3 ml) were collected early in the morning and subsequently stored at −80°C.

Microarray expression analysis

Based on random sampling, Arraystar Human circRNA Microarray analysis version 2.0 (Arraystar, Inc., Rockville, MD, USA) of 6 samples from LA cases and 6 samples from control cases was performed. The sample preparation and microarray hybridization were performed based on the Arraystar's standard protocols. Total RNA from each sample was quantified using the NanoDrop® ND-1000 (NanoDrop Technologies; Thermo Fisher Scientific, Inc., Wilmington, DE, USA). RNA Integrity and genomic DNA contamination test was performed by denaturing agarose gel electrophoresis. Sample labeling and array hybridization were performed according to the manufacturer's protocol (Arraystar Inc.). Briefly, 2,600 ng/µl total RNA (including 28s and 18s ribosomal RNA from each sample was treated with RNase R (Epicentre, Inc.) to enrich circRNA. The enriched RNA was subsequently amplified and transcribed into fluorescent complementary RNA (cRNA) utilizing random primers according to the Arraystar Super RNA Labeling kit protocol (Arraystar, Inc.). The labeled cRNAs were hybridized onto the Arraystar Human circRNA Mircoarrays (8×15K; Arraystar, Inc.) and incubated for 17 h at 65°C in an Agilent hybridization oven. After washing four times in hybridization buffer the labeled cRNAs, slides were scanned with an Agilent G2505C Microarray Scanner System (Agilent Technologies, Inc., Santa Clara, CA, USA).

Data collection and analysis

Scanned images were imported into Agilent Feature Extraction software version 11.0.1.1 (Agilent Technologies, Inc.) for raw data extraction. Quantile normalization of raw data and subsequent data processing were performed using the R software package (R Project for Statistical Computing, Vienna, Austria). After quantile normalization of the raw data, low intensity filtering was performed, and the circRNAs that were flagged as ‘P’ or ‘M’ (‘All Targets Value’) in at least 3 out of 6 samples were retained for further analyses. When comparing profile differences between two groups (including disease vs. control), the ‘fold change’ (i.e., the ratio of the group mean averages) between the groups for each circRNA was computed. The statistical significance of the difference was determined by a t-test. circRNAs with fold changes >1.5 and P<0.05 were selected as significantly differentially expressed circRNAs. circRNA sequences were predicted by bioinformatics methods, as described previously (6).

RT-qPCR detection of hsa_circ_102470, hsa_circ_101396, hsa_circ_102533 and hsa_circ_103783

Total RNA in plasma was extracted using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and was quantified using the NanoDrop® ND-1000, according to the manufacturer's protocol. cDNA was synthesized by RT (Arraystar Super RNA Labeling kit; Arraystar, Inc., Rockville, MD, USA) 3 times using random primers and the Gene Amp PCR system 9700, according to the manufacturer's protocol. A total of 1 µg RNA, 1 µl random (N9), 1.6 µl dNTP mix (2.5 mM dATP, dGTP, dCTP, and dTTP, provided by HyTest Ltd) was combined to make the annealing mixture. This mixture was incubated in a 65°C water bath for 5 min and then put on ice for 2 min. After brief centrifugation at 12,000 × g or 15 min at 4°C, the RT reactant solution (4 µl 5X First-Strand Buffer, 1 µl 0.1 M DTT, 0.3 µl RNase inhibitor and 0.2 µl SuperScript III RT, provided by Invitrogen; Thermo Fisher Scientific, Inc.) was added to a centrifuge tube and incubated at 37°C in a water bath for 1 min. The tube was then incubated at 50°C in a water bath for 60 min, followed by 70°C for 15 min. Subsequently, cDNA was placed on ice. qPCR was performed using Arraystar SYBR®-Green qPCR Master Mix (ROX-), 5 ml on the ViiA™ 7 Real-time PCR system. Cycling conditions were as follows: An initial predenaturation step at 94°C for 20 sec, followed by 40 cycles of denaturation at 95°C for 10 sec, annealing at 60°C for 60 sec and extension at 72°C for 15 sec. The primers used to quantify levels of the 4 circRNAs (hsa_circ_102470, hsa_circ_101396, hsa_circ_102533 and hsa_circ_103783) and GAPDH are presented in Table I. The data were analyzed using the relative values following internal calibration, presented as hsa_circ_102470/GAPDH, hsa_circ_101396/GAPDH, hsa_circ_102533/GAPDH and hsa_circ_103783/GAPDH. Subsequently, the ratios (average relative values in test group divided by the average relative values in control group) of the 4 circRNAs were further analyzed. The 2−∆∆Cq method was used for quantification (5).
Table I.

Primers for reverse transcription-quantitative polymerase chain reaction.

Sequence

GeneForwardReverseAnnealing temperature (°C)Product length (bp)
GAPDH5′GGGAAACTGTGGCGTGAT3′5′GAGTGGGTGTCGCTGTTGA3′60299
hsa_circRNA_1025335′GCTGCCAAAAGCATAACCAA3′5′CCCCTTTTCTGCTAAATGAACTCT3′60198
hsa_circRNA_1037835′AAGCTGTTAGCATGATCCCACC3′5′GATGAAACTTTTCCAAGTGTGGC3′60133
hsa_circRNA_1013965′AAAGGTCCACTTCGTATGCTG3′5′ACTCTGTCATTGGAGCAACTGTAT3′60221
hsa_circRNA_1024705′CCTAAATTTCACGACACCAG3′5′ATTCAGATTGCTCAAGGTAACT3′60144

circRNA, circular RNA.

Prediction of DE genes and the function analysis of DE genes

GO covers three domains, including biological process, cellular component and molecular function. Fisher's exact test is used by professionals to establish whether there is a higher overlap between the DE list and the GO annotation list than expected by chance. The P-value denotes the significance of GO term enrichment in the DE genes. The lower the P-value, the higher the significance of the GO Term (P<0.05 is recommended). Pathway analysis is a functional analysis that maps genes to KEGG pathways. The P-value (EASE-score, Fisher-P-value or Hypergeometric-P-value) denotes the significance of the pathway associated with the conditions; the lower the P-value, the higher the significance of the pathway (The recommended P-value cut-off is 0.05).

Statistical analysis

Data are presented as the mean ± standard deviation (continuous variables) or as a proportion (discrete variables). The differences between groups were analyzed by Student's t-test (continuous variables) or chi-squared test (discrete variables). SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis.

Results

Differential expression of circRNAs

The characteristics of age- and sex-matched test and control group subjects are presented in Table II. Compared with the controls, certain circRNAs exhibited >1.5-fold change (P<0.05) in the LA group; 32 were upregulated and 132 were downregulated. Among the upregulated circRNAs, hsa_circ_103783, hsa_circ_101396 and hsa_circ_102533 exhibited the highest statistically significant difference in expression, while of the downregulated circRNAs, hsa_circ_102470 was identified to exhibit the largest difference in expression between the LA and control groups. The results of the RT-qPCR detection of hsa_circ_102470, hsa_circ_101396, hsa_circ_102533 and hsa_circ_103783 are presented in Fig. 1. The expression of hsa_circ_103783 and hsa_circ_102533 in the test group was significantly higher compared with the control group, with fold increases in expression of 3.67 (P<0.001) and 3.52 (P<0.05), respectively. The expression of hsa_circ_101396 was 1.25-fold higher in the test group compared with the control; however, this was not statistically significant (P=0.05). Comparing the expression of hsa_circ_102470 between the two groups, a 0.8-fold downregulation, which was not statistically significant, was observed in the test group (P=0.39).
Table II.

Subject characteristics.

CharacteristicTotalLAControlP-value
Age, years58±5.759±6.356±2.40.074
Number of males (%)  10 (33.3)  7 (35)3 (30)0.784
Systolic pressure, mmHg150 (±7.1)148 (±3.2)  153 (±11.0)0.059
Diastolic pressure, mmHg  84 (±4.2)  82 (±3.9)  85 (±4.6)0.162

Data are presented as the mean ± standard deviation (continuous variables) or as a proportion (discrete variables). LA, leukoaraiosis.

Figure 1.

Mean relative expression of 4 circRNAs in LA and control groups. Mean relative expression of hsa_circ_102470, hsa_circ_101396, hsa_circ_102533 and hsa_circ_103783 was determined in LA and control groups. circRNAs, circular RNAs; LA, leukoaraiosis. *P<0.05 and **P<0.001.

GO analysis of DE genes

The top 10 most significant enrichment GO terms of the upregulated DE genes are presented in Tables III–V. The biological process was primarily enriched in metabolic processes, including nucleobase-containing compounds, and heterocycle and cellular aromatic compound metabolic processes. The major cellular components were organelles, membrane-bounded organelles, intracellular membrane-bounded organelles and intracellular organelles. The molecular function predominantly enriched in the activity of histone acetyltransferase and acetyl-CoA were L-lysine, N6-acetyltransferase and ion channel activity. The top 10 most significantly enriched GO terms among the downregulated DE genes are presented in Tables VI–VIII. The present study demonstrated that cellular localization was the most enriched biological process of DE genes, and the major cellular components involved were the cytoplasm and cytosol. The molecular function was predominantly enriched in kinase, enzyme and protein kinase binding.
Table III.

Top ten gene ontology BP terms that upregulated genes were enriched in.

BP term, metabolic processEnrichment scoreP-value
Nucleobase-containing compound2.660.002
Heterocycle2.510.003
Cellular aromatic compound2.500.003
Organic cyclic compound2.330.004
Cellular nitrogen compound2.330.004
Regulation of nucleobase-containing compound2.330.004
Regulation of nitrogen compound0.520.005
Nitrogen compound2.240.009
Single organismal cell-cell adhesion2.030.013
Nucleic acid1.860.014

BP, biological process.

Table V.

Top ten MF terms that upregulated genes were enriched in.

MF termEnrichment scoreP-value
Histone acetyltransferase activity2.460.003
Acetyl-CoA:L-lysine2.460.003
N6-acetyltransferase
Ion channel activity2.460.003
Substrate-specific channel activity2.420.004
Channel activity2.340.005
Passive transmembrane transporter activity2.340.005
Enzyme activator activity2.290.005
Anion channel activity2.120.008
N-acetyltransferase activity2.110.008
GTPase activator activity2.090.008

MF, molecular function.

Table VI.

Top ten BP terms that downregulated genes were enriched in.

BP termEnrichment scoreP-value
Cellular localization4.97<0.001
Establishment of localization in cell4.92<0.001
Intracellular transport4.39<0.001
Macromolecular complex subunit organization4.26<0.001
Cytoplasmic transport4.18<0.001
Modification-dependent macromolecule catabolic process4.10<0.001
Organic substance catabolic process3.98<0.001
Catabolic process3.97<0.001
Cytoskeleton organization3.84<0.001
Organelle localization3.83<0.001

BP, biological process.

Table VIII.

Top ten MF terms that downregulated genes were enriched in.

MF termEnrichment scoreP-value
Kinase binding6.17<0.001
Enzyme binding5.05<0.001
Protein kinase binding4.53<0.001
Protein binding3.74<0.001
Transferase activity3.48<0.001
Nucleotide binding3.01<0.001
Nucleoside phosphate binding3.01<0.001
Protein homodimerization activity2.89  0.001
ATP binding2.82  0.002
Protein domain specific binding2.81  0.002

MF, molecular function.

KEGG analysis of DE genes

KEGG enrichment was identified for downregulated DE genes; however, not for upregulated DE genes. The top 10 most significant enrichment KEGG terms are listed in Table IX. The major KEGG item was the insulin signaling pathway, with 10.3% of downregulated DE genes involved in it (Fig. 2; http://www.genome.jp/kegg-bin/show_pathway?scale=1.0&query=&map=hsa04910&scale=0.67&auto_image=&show_description=hide&multi_query= and http://www.kegg.jp/kegg/legal.html).
Table IX.

Top ten KEGG pathways that downregulated genes were enriched in.

KEGG pathwayEnrichment scoreP-value
Insulin signaling pathway, Homo sapiens2.970.001
B cell receptor signaling2.520.003
Thyroid hormone signaling2.510.003
Axon guidance2.380.004
mTOR signaling1.860.014
Transcriptional misregulation in cancer1.770.017
Chemokine signaling1.680.02
Glyoxylate and dicarboxylate metabolism1.640.02
Propanoate metabolism1.640.02
Platelet activation1.620.02

KEGG, Kyoto Encyclopedia of Genes and Genomes.

Figure 2.

Insulin signaling pathway. KEGG enrichment analysis identified that genes that were significantly downregulated in patients with leukoaraiosis compared with controls were enriched in the insulin signaling pathway. The yellow boxes indicate the main compounds in the insulin signaling pathway.

Discussion

At present, understanding of the pathogenesis of LA remains to be fully elucidated, and there no reliable indicator for the early diagnosis of LA in the hypertension population. Previous studies have eported that LA may be associated with various factors, including age, sex (7), hypertension (2), small vessel disease and atherosclerosis (8). Hypertension is one of the most important established risk factors for LA (9), and pulse pressure was previously demonstrated to be independently associated with LA, regardless of classical cardiovascular risk factors in elderly men (10). However, patients with hypertension do not necessarily suffer from LA. To predict the potential for development of LA among patients with hypertension, the present study investigated potential predictors at the circRNA level. Previously, circRNA was demonstrated to be a highly prevalent RNA species in the human transcriptome (6), and they may have important roles in the regulation of gene expression (11). circRNA expression levels can be >10-fold higher compared with their linear isomers (6,12). The two most important properties of circRNAs are highly conserved sequences and have a high degree of stability in mammalian cells (13). Certain circRNAs regulate gene expression by serving as competing endogenous RNAs (14). circRNAs block the inhibitory effect of microRNAs (miRNAs) on the target RNA by combining with miRNAs, so as to regulate the expression level of the target RNA (15). Currently, the circRNA with the most compelling evidence for a biological function is the miRNA-7 sponge, CDR1as (16). miRNA-7 was previously demonstrated to serve a key role in Parkinson's and Alzheimer's diseases (17,18). Although an increasing number of studies have investigated the potential functions of circRNAs in the brain, to the best of our knowledge, the present study is the first to investigate the association between circRNAs and LA. The current study was the first to construct a spectrum of differentially expressed circRNAs in patients with LA, and to identify potential biomarkers for the diagnosis of LA and its pathogenesis. At present, there is no circRNA database for LA. The present study aimed to search a circRNA database for patients with LA and hypertension, via an Arraystar Human circRNA Microarray analysis of 6 test samples and 6 control samples. Subsequently, 32 upregulated and 132 downregulated circRNAs were screened out. Furthermore, 3 upregulated circRNAs (hsa_circ_101396, hsa_circ_102533 and hsa_circ_103783) and 1 downregulated circRNA (hsa_circ_102470) were selected based on a >1.5 fold-change (P<0.05), which were further assessed by RT-qPCR. The results of the current study demonstrated that the exonic RNAs, including hsa_circ_102533 (3.52-fold; P<0.05) and hsa_circ_103783 (3.67-fold; P<0.001), were significantly upregulated in the LA patients compared with the control group, indicating the potential diagnostic value of certain circRNAs for LA. GO enrichment analysis of the upregulated DE genes indicated that DE genes were primarily associated with metabolic processes, organelles and the activity of certain transferases. However, it remains to be elucidated whether such gene products have the potential to be novel detectors for LA. In addition, GO and KEGG analysis of downregulated DE genes indicated that DE genes were primarily enriched in the cytoplasm, kinase binding and the insulin signaling pathway. The insulin signaling pathway was revealed to be pleiotropic, and included c-Cbl-associated protein, insulin receptor substrate-1, mitogen activated protein kinase, plasma cell glycoprotein-1, phosphoinositide-dependent kinase, protein kinase C and phosphatidylinositol 3-kinase (PI3-K). The involvement of phosphatidylinositol 3-kinase/protein kinase B (PI3-K/Akt) -dependent signaling pathways were found in normal cellular functions. The dysfunction of this signaling pathway has a pivotal role in atherosclerosis (19) and hypertension (20). Therefore, it was hypothesized that the PI3-K/Akt-dependent signaling pathway may contribute to the pathological changes of LA. However, this requires further investigation. In conclusion, DE circRNAs were identified between patients with LA and controls among a hypertension population. The present study indicated that the upregulated circRNAs, hsa_circ_102533 and hsa_circ_103783, may have potential as biomarkers for the diagnosis of LA. GO and KEGG enrichment analyses of DE genes indicated that the DE genes were associated with the pathogenesis of LA. However, due to the limited number of plasma samples of LA, the present study only analyzed the expression of 4 circRNAs in 20 plasma samples with LA and 10 control samples. Future studies should increase the sample size to further confirm the diagnostic value of hsa_circ_102533 and hsa_circ_103783 for LA. Importantly, the conclusions were based on a large number of early experimental results; therefore, the specific mechanisms requires further investigation.
Table IV.

Top ten gene ontology CC terms that upregulated genes were enriched in.

CC termEnrichment scoreP-value
Organelle4.48<0.001
Membrane-bounded organelle4.24<0.001
Intracellular membrane-bounded organelle3.68<0.001
Intracellular organelle3.46<0.001
SAGA-type complex2.97  0.001
Nucleus2.83  0.001
Nuclear part2.18  0.007
Nuclear lumen2.16  0.007
Histone acetyltransferase complex2.12  0.008
Intracellular organelle part2.11  0.008

CC, cellular component.

Table VII.

Top ten CC terms that downregulated genes were enriched in.

CC termEnrichment scoreP-value
Cytoplasm8.17<0.001
Cytosol8.16<0.001
Membrane-bounded organelle6.11<0.001
Cytoplasmic part5.46<0.001
Intracellular part5.42<0.001
Organelle5.33<0.001
Intracellular5.12<0.001
Intracellular organelle4.20<0.001
Intracellular membrane-bounded organelle4.18<0.001
Macromolecular complex3.36<0.001

CC, cellular component.

  20 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  The expanding repertoire of circular RNAs.

Authors:  Paul N Valdmanis; Mark A Kay
Journal:  Mol Ther       Date:  2013-06       Impact factor: 11.454

Review 3.  Circular RNAs: splicing's enigma variations.

Authors:  Matthias W Hentze; Thomas Preiss
Journal:  EMBO J       Date:  2013-03-05       Impact factor: 11.598

4.  Circular RNAs are a large class of animal RNAs with regulatory potency.

Authors:  Sebastian Memczak; Marvin Jens; Antigoni Elefsinioti; Francesca Torti; Janna Krueger; Agnieszka Rybak; Luisa Maier; Sebastian D Mackowiak; Lea H Gregersen; Mathias Munschauer; Alexander Loewer; Ulrike Ziebold; Markus Landthaler; Christine Kocks; Ferdinand le Noble; Nikolaus Rajewsky
Journal:  Nature       Date:  2013-02-27       Impact factor: 49.962

5.  Repression of alpha-synuclein expression and toxicity by microRNA-7.

Authors:  Eunsung Junn; Kang-Woo Lee; Byeong Seon Jeong; Teresa W Chan; Joo-Young Im; M Maral Mouradian
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-23       Impact factor: 11.205

6.  Leukoaraiosis and ambulatory blood pressure load in a healthy elderly cohort study: the PROOF study.

Authors:  John Avet; Vincent Pichot; Jean-Claude Barthélémy; Bernard Laurent; Arnauld Garcin; Frédéric Roche; Sébastien Celle
Journal:  Int J Cardiol       Date:  2013-11-23       Impact factor: 4.164

7.  Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types.

Authors:  Julia Salzman; Charles Gawad; Peter Lincoln Wang; Norman Lacayo; Patrick O Brown
Journal:  PLoS One       Date:  2012-02-01       Impact factor: 3.240

8.  Transcriptome-wide discovery of circular RNAs in Archaea.

Authors:  Miri Danan; Schraga Schwartz; Sarit Edelheit; Rotem Sorek
Journal:  Nucleic Acids Res       Date:  2011-12-02       Impact factor: 16.971

9.  Circular RNA (circRNA) in Alzheimer's disease (AD).

Authors:  Walter J Lukiw
Journal:  Front Genet       Date:  2013-12-31       Impact factor: 4.599

10.  Age- and sex-specific rates of leukoaraiosis in TIA and stroke patients: population-based study.

Authors:  Michela Simoni; Linxin Li; Nicola L M Paul; Basil E Gruter; Ursula G Schulz; Wilhelm Küker; Peter M Rothwell
Journal:  Neurology       Date:  2012-09-05       Impact factor: 9.910

View more
  1 in total

1.  Transcriptome Sequencing Identifies Potential Biomarker for White Matter Lesions Diagnosis in the Hypertension Population.

Authors:  Wendi Wang; Pei Sun; Fengyue Han; Chunjuan Wang; Yongxiang Wang; Xiang Wang; Lin Cong; Chuanqiang Qu
Journal:  Neurochem Res       Date:  2021-05-26       Impact factor: 3.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.